Crossmark

Low serum albumin levels and the nongerminal center B-cell subtype according to the Hans algorithm as strong prognostic factors in ≥ 80-year-old patients with large B-cell lymphoma treated with rituximab-containing chemotherapy

Crossref DOI link: https://doi.org/10.1007/s00277-026-06818-3

Published Online: 2026-01-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kawashima, Ichiro

Nakadate, Ayato

Hyuga, Hideto

Matsuura, Minori

Sakamoto, Yuma

Suzuki, Jun

Kumagai, Takuma

Suzuki, Megumi

Yamanda-Koshiishi, Megumi

Yamamoto, Takeo

Nakajima, Kei

Oishi, Naoki

Kondo, Tetsuo

Kirito, Keita
Funding

Funding for this research was provided by:

University of Yamanashi
License Information

Text and Data Mining valid from 2026-01-20

Version of Record valid from 2026-01-20
More Information

Article History

Received: 6 November 2025

Accepted: 5 January 2026

First Online: 20 January 2026

Declarations

:

: This study was approved by the Ethics Committee of the University of Yamanashi (Approval No. 2357). In accordance with the committee’s guidelines, informed consent was obtained using an opt-out approach. Information regarding the study was made publicly available through the university’s website and/or bulletin boards, and participants were given the opportunity to decline participation. All patient data were anonymized prior to analysis.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below